Detalhe da pesquisa
1.
An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma.
CA Cancer J Clin
; 72(5): 454-489, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35708940
2.
SMARCB1 regulates the hypoxic stress response in sickle cell trait.
Proc Natl Acad Sci U S A
; 120(21): e2209639120, 2023 05 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37186844
3.
Efficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell Carcinoma.
Oncologist
; 2024 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38478923
4.
Racial Disparities in MiT Family Translocation Renal Cell Carcinoma.
Oncologist
; 28(11): 1009-1013, 2023 Nov 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37315151
5.
Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas.
Oncologist
; 28(5): 433-439, 2023 05 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36640141
6.
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience.
Oncologist
; 28(8): 714-721, 2023 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36952233
7.
Treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy.
Oncologist
; 2023 Nov 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38035767
8.
Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.
Cancer
; 128(11): 2085-2097, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35383908
9.
Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas.
Oncologist
; 27(12): 1041-1047, 2022 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35979929
10.
Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation.
BJU Int
; 129(5): 610-620, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34228889
11.
Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study.
Acta Oncol
; 61(1): 52-57, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34736367
12.
Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial.
Lancet Oncol
; 22(12): 1732-1739, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34717797
13.
Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study.
Int J Cancer
; 149(2): 403-408, 2021 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33709428
14.
Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience.
Int J Cancer
; 149(2): 387-393, 2021 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33739450
15.
Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies.
Oncologist
; 26(6): 476-482, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33792094
16.
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
N Engl J Med
; 378(14): 1277-1290, 2018 Apr 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29562145
17.
Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.
BMC Cancer
; 21(1): 904, 2021 Aug 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34364385
18.
Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy.
Cancer
; 126(17): 3950-3960, 2020 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32515845
19.
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.
Cancer
; 126(18): 4156-4167, 2020 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32673417
20.
Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis.
Oncologist
; 25(3): 252-258, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32162795